 HOUSTON, March 24, 2021 PRNewswire -- Moleculin Biotech, Inc., Nasdaq: MBRX Moleculin or the Company, a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results for the year ended December 31, 2020 and provided a business update. Recent Milestones and Accomplishments: Corporate Strategy and Events Raised gross proceeds of approximately 81 million through registered equity offering and ATM program in 1Q21 providing runway into 2025 based on the Companys current RD spending levels. 